CXCR2 blockade overcomes the NETosis-mediated resistance to MEK inhibition in pancreatic cancer models
Journal of Clinical Investigation · 2026
DOI: 10.1172/jci196622 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Brian Herbst und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center. Hauptthemen laut MEDLINE: Receptors, Interleukin-8B, Pancreatic Neoplasms, Drug Resistance, Neoplasm, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Institute.
Abstract (Originalsprache)
Single-agent anti-PD-1 antibodies are ineffective for pancreatic ductal adenocarcinoma (PDAC) due to the immunosuppressive tumor-microenvironment (TME). KRAS mutations contribute to the inflammatory TME and therapeutic resistance by upregulating IL-8 via MAPK pathways. Thus, this study attempted to overcome the resistance to anti-PD-1 antibodies by targeting downstream KRAS-effectors. The study found that the resistance to anti-PD-1 antibodies can be overcome through MEK1/2-inhibition. The combination of anti-PD-1 antibodies and MEK inhibitors displayed antitumor activity in Kras mutated (Kras mut ) KPC mouse tumors, but not WT (Kras WT ) Panc02 tumors. The combination of anti-PD-1 antibodies and MEK inhibitors induced recruitment of tumor-associated neutrophils (TANs) via CXCR2, an IL-8 receptor, and increased memory CD8 + T cells and IFN-γ production in treatment-sensitive tumors. However, larger tumors still resisted the combination of anti-PD-1 antibody and MEK inhibitor, likely due to hypoxia/necrosis-induced NETosis and associated paucity of CD8 + T cells. The subsequent addition of anti-CXCR2 antibody overcame this resistance by blocking TAN-infiltration to hypoxic/necrotic areas. Consistently, a risk-score based on the NETosis-MAPK signaling interaction is significantly associated with poorer survival in human PDAC. This study thus provides a new venue for overcoming resistance to strategies targeting KRAS signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center.
- Graduate Program in Cellular and Molecular Medicine.
- Pancreatic Cancer Precision Medicine Center of Excellence Program.
- Bloomberg-Kimmel Institute for Cancer Immunotherapy.
- Skip Viragh Center for Pancreatic Cancer, and.
- Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Förderung
- National Cancer Institute
Zitieren
APA
Herbst, B., Blair, A., Li, Y., Jaffee, E. M., & Zheng, L. (2026). CXCR2 blockade overcomes the NETosis-mediated resistance to MEK inhibition in pancreatic cancer models. Journal of Clinical Investigation. https://doi.org/10.1172/jci196622
Vancouver
Herbst B, Blair A, Li Y, Jaffee EM, Zheng L. CXCR2 blockade overcomes the NETosis-mediated resistance to MEK inhibition in pancreatic cancer models. Journal of Clinical Investigation. 2026. doi:10.1172/jci196622
BibTeX
@article{Herbst2026,
author = {Herbst, Brian and Blair, Alex and Li, Yiming and Jaffee, Elizabeth M and Zheng, Lei},
title = {CXCR2 blockade overcomes the NETosis-mediated resistance to MEK inhibition in pancreatic cancer models},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci196622}
}
EUVIMED